CCC 2012: Extending Findings from the RAFT CRT Trial
The Heart Institute’s landmark RAFT trial, released in 2010, showed that cardiac resynchronization therapy (CRT) in combination with an implantable cardioverter defibrillator (ICD) device reduces the risk death by 24 per cent in patients with mild to moderate heart failure. Two new studies mined
CCC 2012: The Intersection of Diabetes and Heart Disease
An Overview from the Cardiovascular Perspective Diabetes is a large and growing problem in Canada, with diabetic patients at much greater risk for dangerous cardiovascular events, including recurrent heart attacks and the development of heart failure. Because it’s such a major contributor to heart
AHA 2012: Heart Institute News and More
Once again, the University of Ottawa Heart Institute had more than 40 clinical and research presentations on the program at the annual American Heart Association Scientific Sessions. These, along with other major developments in the world of cardiovascular medicine, made for a lively conference. New
AHA 2012: New Class of Drugs Substantially Lowers “Bad” Cholesterol
Some of the biggest news to come out of AHA this year was the results from preliminary clinical trials of two new LDL cholesterol-lowering drugs that show a substantial decrease in LDL levels well below the reductions seen with statins or ezetimibe alone. The new drugs belong to a class called PCSK9
AHA 2012: Invited Experts
Several Heart Institute staffers offered their expertise in invited talks touching on a broad range of topics. Scientist Erik Suuronen, PhD, uses tissue engineering techniques to develop methods for regenerating damaged heart muscle. In his presentation, called “The Matrix: Stem Cell Delivery
AHA 2012: Stem Cells for Cardiac Repair
The use of stem cells for regenerating damaged heart tissue offers great potential, but many technical questions remain. Understanding which cell types are most beneficial and how they should be employed is a central issue. Several clinical trials involving stem cells were presented at AHA. Two were
AHA 2012: Engineering Success in Heart Failure
Successfully managing heart failure is one the looming issues for cardiovascular medicine, with prevalence expected to grow significantly over the coming decades. The plenary session “Engineering Success in Heart Failure” looked at where things are headed, from therapy to devices to delivery of care
Transcatheter Aortic Valve Implantation Gallery
Interventional cardiologists at the University of Ottawa Heart Institute are championing broad-based innovation by using catheter-based procedures to treat a variety of conditions. This gallery highlights a minimally invasive procedure, called TAVI (transcatheter aortic valve implantation), for
Interventional Cardiologists Champion Broad Innovation
Somewhere between traditional cardiologists and cardiac surgeons sit interventional cardiologists. Like surgeons, interventionists get blood on their gowns in the process of correcting structural problems of the heart, but their approach is more subtle and less invasive. Spending their days in the
The Heart Institute Welcomes New Scientific Director
“We have a long way to go to cure heart disease.” This is the view of Dr. Peter Liu, the recently appointed Scientific Director at the University of Ottawa Heart Institute. Despite the state-of-the-art care available today, doctors are yet to restore a patient’s heart and blood vessels to their